Align Technology
Align Technology's revenue rose 0.9% to $4.0 billion in fiscal 2025. Its operating margin was 13.5%, down from 15.2% a year earlier. Free cash flow was $491 million, down 21.2%. It paid out $466 million in dividends and buybacks, 95% of free cash flow. The diluted share count fell 3.2%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Revenue and margins
Net income and earnings per share
From fiscal 2016 to 2025, earnings per share grew 10.3% a year and net income 9.0% a year, as buybacks cut the share count by 11%.
Returns on capital
Cash flow
Payouts and share count
Valuation
Two ways to value Align Technology yourself, both starting from its filings: a discounted cash flow model and the price-to-earnings method.
Discounted cash flow (DCF)
A discounted cash flow (DCF) model values a business as the cash it may generate in future, discounted back to today. The starting figures come from Align Technology's 10-K (or, for net cash and shares, its latest 10-Q) and the assumptions are yours: start from one of three example scenarios, then change any figure to see what it implies for a share, and how that compares with the last share price.
Value per share on three example scenarios, from Align Technology's fiscal 2025 free cash flow of $491M, net cash of $1.1B at December 31, 2025 and 73 million diluted shares, from its filings. The scenarios are fitted to Align Technology: the base scenario's growth in years 1 to 5 is its revenue growth over the last 3 years, 2.6% a year; the cautious and optimistic ones are lower and higher, and growth in years 6 to 10 is halfway to the long-run rate. The base scenario's discount rate is 9% for a business of moderate risk (Health Care Supplies); the cautious and optimistic ones use a point more and a point less. Select one to load it into the calculator. These are the model's arithmetic on those assumptions, not a forecast or a price target.
- Last close, October 26, 2026
- $152.26
- Value on these assumptions, against the last close
- —
- Cash flows in years 1 to 10, valued today
- —
- Everything after year 10, valued today
- —
- Plus net cash
- —
- Share of value from after year 10
How the value changes with two assumptions
Price-to-earnings (P/E) method
Another common way to value a company is to multiply its earnings per share by a price-to-earnings (P/E) multiple: the number of years of today's earnings an investor pays for a share. A higher multiple usually means investors expect earnings to grow. Choose a multiple, for example from similar companies, to see the value it gives.
Value per share on three example scenarios, from Align Technology's earnings per share of $5.74 (over the last four quarters). Each grows earnings for a year at the cash flow scenarios' rates and applies a multiple to next year's earnings: 28×, the middle of Align Technology's own P/E today, its peers' median and its sector's median (the Health Care median) for the base scenario, 20% less and more for the cautious and optimistic ones. The price is brought back a year at 10%, 9% and 8%. Select one to load it into the calculator. These are the model's arithmetic on those assumptions, not a forecast or a price target.
- Last close, October 26, 2026
- $152.26
- Value at this multiple, against the last close
- —
- Align Technology's P/E at the last close
- 26.5×
| Company | Last close | Earnings per share | P/E today |
|---|---|---|---|
| West Pharmaceutical ServicesWST | $394.73 | $7.81 | 50.5× |
| EnvistaNVST | $23.66 | $0.58 | 40.8× |
| Align TechnologyALGN | $152.26 | $5.74 | 26.5× |
| Cooper CompaniesCOO | $61.14 | $2.92 | 20.9× |
Balance sheet
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 1,171 | 1,000 | 973 | 1,044 | 1,095 |
| Debt incl. finance leases | 0 | 0 | 0 | 0 | 0 |
| Net debt (negative means net cash) | −1,171 | −1,000 | −973 | −1,044 | −1,095 |
| Net debt to EBITDA | −1.1x | −1.3x | −1.2x | −1.4x | −1.4x |
| Debt to equity | 0.0x | 0.0x | 0.0x | 0.0x | 0.0x |
| Interest coverage | — | — | — | — | — |
| Current ratio | 1.3x | 1.3x | 1.2x | 1.2x | 1.4x |
| Quick ratio | 1.2x | 1.1x | 1.0x | 1.1x | 1.2x |
Insider trades
Over the 12 months between October 27, 2025 and October 26, 2026, no insider bought Align Technology shares on the open market, and 1 insider sold $1.5 million.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Feb 18, 2026 | John MoriciEVP, Chief Financial Officer | Sold | 7,969 | $189.31 | $1.5 million | Form 4 |
Piotroski F-score
The F-score counts how many of nine simple tests of profitability, funding and efficiency a company passed in a year (Piotroski, 2000). The more tests passed, the stronger the year: 8 or 9 is strong, 0 to 2 weak. Companies that report no gross profit are scored on the other eight.
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Pass | Pass | Pass |
| Cash from operations is positive | Pass | Pass | Pass |
| Return on assets rose | Pass | Fail | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Fail | Fail | Fail |
| Current ratio rose | Fail | Pass | Pass |
| Share count didn't rise | Pass | Pass | Pass |
| Gross margin rose | Fail | Fail | Fail |
| Revenue rose relative to assets | Pass | Pass | Fail |
| F-score | 6 of 9 | 6 of 9 | 5 of 9 |
| Accruals ratio | −5.7% | −5.2% | −2.9% |
Compare
Put Align Technology side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Align Technology | FY25 | 0.9% | 13.5% | 12.2% | 13.3% | −1.4x | 5 | |
| Cooper Companies | FY25 | 5.1% | 16.7% | 10.6% | 4.3% | 2.3x | 5 | Compare |
| Dentsply Sirona | FY25 | −3.0% | −11.5% | 2.8% | −9.9% | — | 6 | Compare |
| West Pharmaceutical Services | FY25 | 6.2% | 19.0% | 15.2% | 18.7% | −0.8x | 9 | Compare |
| Envista | FY25 | 8.3% | 8.0% | 8.5% | 3.2% | 0.7x | 7 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 1,080 | 1,473 | 1,966 | 2,407 | 2,472 | 3,953 | 3,735 | 3,862 | 3,999 | 4,035 |
| Revenue growth | 27.7% | 36.4% | 33.5% | 22.4% | 2.7% | 59.9% | −5.5% | 3.4% | 3.5% | 0.9% |
| Gross profit | 815 | 1,117 | 1,448 | 1,744 | 1,763 | 2,935 | 2,634 | 2,707 | 2,799 | 2,711 |
| Research and development | 76 | 98 | 129 | 157 | 175 | 250 | 305 | 347 | 364 | 370 |
| Operating income | 249 | 354 | 467 | 542 | 387 | 976 | 643 | 643 | 608 | 546 |
| Net income | 190 | 231 | 400 | 443 | 1,776 | 772 | 362 | 445 | 421 | 410 |
| Diluted EPS (US$) | 2.33 | 2.83 | 4.92 | 5.53 | 22.41 | 9.69 | 4.61 | 5.81 | 5.62 | 5.65 |
| Diluted shares (millions) | 82 | 82 | 81 | 80 | 79 | 80 | 78 | 77 | 75 | 73 |
| Cash flow | ||||||||||
| Cash from operations | 248 | 438 | 555 | 747 | 662 | 1,172 | 569 | 786 | 738 | 593 |
| Capital expenditure | 71 | 196 | 223 | 150 | 155 | 401 | 292 | 178 | 116 | 102 |
| Free cash flow | 177 | 243 | 331 | 598 | 507 | 771 | 277 | 608 | 623 | 491 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 96 | 104 | 300 | 400 | 0 | 375 | 435 | 592 | 353 | 466 |
| Acquisitions | 0 | 9 | 0 | 0 | 421 | 8 | 12 | 0 | 77 | 0 |
| Stock-based compensation | 54 | 59 | 71 | 88 | 98 | 114 | 133 | 154 | 174 | 186 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 640 | 722 | 735 | 869 | 961 | 1,171 | 1,000 | 973 | 1,044 | 1,095 |
| Debt incl. finance leases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total assets | 1,396 | 1,784 | 2,052 | 2,501 | 4,830 | 5,942 | 5,948 | 6,084 | 6,215 | 6,234 |
| Total liabilities | 401 | 630 | 800 | 1,154 | 1,596 | 2,319 | 2,347 | 2,453 | 2,363 | 2,184 |
| Shareholders' equity | 999 | 1,154 | 1,253 | 1,346 | 3,234 | 3,623 | 3,601 | 3,630 | 3,852 | 4,049 |
| Margins and ratios | ||||||||||
| Gross margin | 75.5% | 75.8% | 73.6% | 72.5% | 71.3% | 74.3% | 70.5% | 70.1% | 70.0% | 67.2% |
| Operating margin | 23.1% | 24.0% | 23.7% | 22.5% | 15.7% | 24.7% | 17.2% | 16.7% | 15.2% | 13.5% |
| Net margin | 17.6% | 15.7% | 20.4% | 18.4% | 71.8% | 19.5% | 9.7% | 11.5% | 10.5% | 10.2% |
| Free cash flow margin | 16.4% | 16.5% | 16.9% | 24.8% | 20.5% | 19.5% | 7.4% | 15.7% | 15.6% | 12.2% |
| Return on capital | 57.8% | 57.5% | 86.0% | 87.3% | 28.1% | 31.5% | 15.3% | 17.0% | 15.4% | 13.3% |
| Return on equity | 20.5% | 21.5% | 33.2% | 34.1% | 77.5% | 22.5% | 10.0% | 12.3% | 11.3% | 10.4% |
| Return on assets | 14.8% | 14.6% | 20.9% | 19.4% | 48.5% | 14.3% | 6.1% | 7.4% | 6.8% | 6.6% |
| Net debt to EBITDA | −2.4x | −1.8x | −1.4x | −1.4x | −2.0x | −1.1x | −1.3x | −1.2x | −1.4x | −1.4x |